Atlas Trials

A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment

Clinical trial NCT04338269 · TERMINATED

Trial details

NCT number
NCT04338269
Sponsor
Hoffmann-La Roche
Status
TERMINATED
Phase
Phase 3
Study type
INTERVENTIONAL
Carcinoma, Renal Cell
Start date
2020-07-28
Primary completion
2023-01-03
Enrollment
522

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.